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Abstract
Background: Failure to retain HIV-positive pregnant women on antiretroviral therapy (ART) leads to increased mortality
for the mother and her child. This study evaluated different retention measures for women’s engagement along the
continuum of care for prevention of mother-to-child transmission (PMTCT) option B+ services in Mozambique.
Methods: We compared ‘point’ retention (patient’s presence in care 12-month post-ART initiation or any time thereafter)
with the following definitions: alive and in care 12month post-ART initiation (Ministry of Health; MOH); attendance at a
health facility up to 15-month post-ART initiation (World Health Organization; WHO); alive and in treatment at 1-, 2-, 3-, 6-,
9-, and 12-month post-ART initiation (Inter-Agency Task Team; IATT); and alive and in care 12-month post-ART initiation
with ≥75% appointment adherence during follow-up (i.e. ‘appointment adherence’ retention) or with ≥75% of
appointments met on time during follow-up (i.e. ‘on-time adherence’ retention). Kaplan-Meier survival curves were
produced to assess variability in retention rates. We used ‘on-time adherence’ retention as our reference to estimate
sensitivity, specificity, and proportion of misclassified patients.
(Continued on next page)
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: laurence_ahoua@yahoo.fr
1University of Bordeaux, INSERM, Bordeaux Population Health Research
Center, Team IDLIC, UMR 1219, Université de Bordeaux, Case 11, 146 rue Léo
Saignat, 33076 Bordeaux Cedex, France
2Mailman School of Public Health, ICAP at Columbia University, Rua Francisco
Matange, 224/246, Caixa Postal n.°1747, Maputo, Mozambique
Full list of author information is available at the end of the article
Ahoua et al. BMC Public Health          (2020) 20:322 
https://doi.org/10.1186/s12889-020-8406-5
(Continued from previous page)
Results: Considering the ‘point’ retention definition, 16,840 HIV-positive pregnant women enrolled in option B+ PMTCT
services were identified as ‘retained in care’ 12-month post-ART initiation. Of these, 60.3% (95% CI 59.6–61.1), 84.8% (95%
CI 84.2–85.3), and 16.4% (95% CI 15.8–17.0) were classified as ‘retained in care’ using MOH, WHO, and IATT definitions,
respectively, and 1.2% (95% CI 1.0–1.4) were classified as ‘retained in care’ using the ‘≥75% on-time adherence’ definition.
All definitions provided specificity rates of ≥98%. The sensitivity rates were 3.0% with 78% of patients misclassified
according to the WHO definition and 4.3% with 54% of patients misclassified according to the MOH definition. The ‘point’
retention definition misclassified 97.6% of patients. Using IATT and ‘appointment adherence’ retention definitions,
sensitivity rates (9.0 and 11.7%, respectively) were also low; however, the proportion of misclassified patients was smaller
(15.9 and 18.3%, respectively).
Conclusion: More stringent definitions indicated lower retention rates for PMTCT programs. Policy makers and program
managers should include attendance at follow-up visits when measuring retention in care to better guide planning, scale-
up, and monitoring of interventions.
Keywords: PMTCT, Option B + , Retention, Sensitivity, Specificity
Background
In 2015, the World Health Organization (WHO) recom-
mended that all HIV-positive pregnant women be pro-
vided with lifelong antiretroviral therapy (ART)
regardless of their CD4 count and WHO staging, also
called “option B+” [1]. Compared to previous prevention
of mother-to-child transmission (PMTCT) of HIV regi-
mens, such as option A (short term anti-retroviral
prophylaxis) or option B (triple anti-retroviral until end
of breastfeeding) [2], option B+, by providing the same
antiretroviral triple-combination to all HIV-positive
pregnant women for life, has the advantages of lowering
the risk of HIV transmission to the male partners since
being on ART will make women less infectious, reducing
the risk of MTCT of HIV in subsequent pregnancies
while reducing the risk of child infection to less than 5%
in resources limited settings [1].
Retention in PMTCT care has both individual and
public health implications. For mother-infant pairs, be-
ing in care contributes to higher maternal ART adher-
ence, better viral suppression, and ensures better post-
natal care, including full ART prophylaxis and complete
infant testing for HIV-exposed infants (HEI) [3, 4]. In
contrast, failure to be retained in care can lead to de-
layed or inconsistent use of antiretroviral medications,
higher risk of maternal viral load failure, and increased
morbidity and mortality for the mother and her child
[5–7]. In addition, recent publications have reported an
upward trend in acquired drug resistance to first-line
ART across low- and middle-income countries, princi-
pally due to sub-optimal viral suppression [8–10].
Therefore, non-achievement of viral suppression can
lead to a higher risk of HIV transmission and secondary
infections with acquired drug resistance strains, and is
therefore considered a public health threat [11].
When referring to retention in care, publications often
consider ‘point’ retention, which is defined in relation to
a patient’s presence in care at a certain time point [12].
For women and children enrolled in PMTCT services,
attendance at a clinic at a certain time point is often
considered to be full retention over this time period.
While such a simple definition is useful, it has been
demonstrated that between one- and two-thirds of HIV-
infected adult patients are not in regular care [13].
Therefore, regularity of attendance is an important par-
ameter to consider if the quality of engagement in care
is to be evaluated [14].
To address the shortcomings in this simple definition,
attempts have been made to better measure retention in
care in PMTCT services [15, 16]. In 2014, a WHO mon-
itoring and evaluation working group published consoli-
dated strategic information guidelines and proposed that
retention in care of HIV-infected pregnant and breast-
feeding women was equivalent to attendance at a health
facility at 12-month post-initiation of ART, or at any
time up to 3 months later [15]. The 12-month time point
was agreed to align with the adult ART monitoring
guidelines; however, it fails to address HIV transmission
risk beyond 12 months due to prolonged breastfeeding.
In 2015, the Inter-Agency Task Team (IATT) on Chil-
dren and HIV and AIDS defined maternal retention as
‘the proportion of HIV-positive pregnant and/or breast-
feeding women on ART alive and in treatment at 1, 2,
and 3 months post-ART initiation (early retention), and
then at 6, 9, and 12 months post-ART initiation’, where
retention was considered as a continuous engagement
[16]. Despite such efforts, there is no consensus on what
constitutes ‘retention in care’, and no gold standard has
been determined to date. In 2010, Mugavero et al. pro-
vided a synopsis of five commonly used definitions of re-
tention in HIV care and treatment services, ranging
from a simple count of the number of missed visits to a
more complex medical visit performance measure that
incorporated elements of appointment consistency and
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gaps in care [13]. While that study provided important
insights on methodological and conceptual strengths
and limitations of each definition, no comparative ana-
lysis of these definitions has been undertaken. We hy-
pothesized that ‘point’ retention might overestimate the
level of engagement in care of women enrolled in
PMTCT programs, giving a false image of clinical and
programmatic success. In a high HIV-burden country
such as Mozambique, women’s engagement should be
more precisely assessed in order to identify windows of
opportunity for possible improvement throughout the
PMTCT care continuum and to better account for the
number of children in need of ART [17].
In this study, we aimed to answer the following ques-
tions: What is the effect of different definitions of reten-
tion in care on the interpretation of women’s engagement
along the PMTCT continuum of care programs under op-
tion B+ in Mozambique? What are the advantages and
limitations of each definition? Finally, what other mea-
sures of retention besides ‘point’ retention could more ac-
curately reflect the nature of women’s engagement along
the PMTCT care continuum? Specifically, this study i)
assessed the variability of different measures of retention
at 12months post-ART initiation under PMTCT option
B+ programs using six different definitions of retention in
care, (ii) compared the sensitivity and specificity of the dif-
ferent definitions in detecting women fully engaged in
care at 12months post-ART initiation, and (iii) discussed
the programmatic implications of each definition in the
context of PMTCT option B+ programs.
Methods
Study design
This was a retrospective cohort study involving second-
ary analysis of routinely collected data.
Setting
Data were extracted from all sites with available elec-
tronic patient-level databases (ePLD), representing a
total of 86 Ministry of Health (MOH) facilities in Nam-
pula and Zambézia Provinces in Mozambique that were
included in the analysis. All of these sites provided
PMTCT option B+ and HIV care and treatment services
with the support of ICAP at Columbia University
through funding from the United States President’s
Emergency Plan for AIDS Relief (PEPFAR).
Officially adopted in 2013, the option B+ strategy in
Mozambique uses a ‘one-stop-model’ and ‘Test and
Treat’ approach, wherein pregnant and breastfeeding
women are counseled and tested in mother and child
health (MCH) services and, if found HIV-positive, are
started on lifelong ART that same day. HIV care and
treatment are integrated within MCH services and ART
provision is administered by nurses. For HIV-positive
pregnant women, a second consultation occurs within
the first week post-ART initiation, and a monthly clin-
ical follow-up is conducted during the first 6 months of
ART, followed by bi-monthly follow-ups during breast-
feeding until 12 months of treatment and bi-annually
thereafter until the end of breastfeeding. ART counseling
and drug pickup are conducted on a monthly basis for
the first year of treatment. Routine viral load (VL) moni-
toring is recommended at 3 and 12months post-ART
initiation and annually thereafter. HIV-positive women
are followed-up in MCH services until the final HIV sta-
tus of the exposed infant is determined [18]. More de-
tailed descriptions of the PMTCT program settings and
data sources are described elsewhere [19].
The Mozambique provinces targeted for the study offi-
cially implemented option B+ in July 2013. Of all HIV-
positive women who were enrolled in PMTCT option
B+ programs and who were started on ART between
July 1, 2013 and December 31, 2017, we selected those
who were considered as ‘retained in care’ at 12 months
post-ART initiation according to the ‘point’ retention
definition (i.e. patient alive and present in care at 12
months post-ART initiation, or any time thereafter) and
with a follow-up time of at least 12 months under ART
to allow complete assessment of engagement in care
during the first year of treatment. These selected women
constituted the basis of comparison for the subsequent
analyses assessing variability in different definitions con-
cerning retention measures.
Comparing definitions
The ‘point’ retention definition was compared with the
following five definitions: MOH [20], WHO [15], IATT
[16], ‘appointment adherence’ retention [13], and ‘on-
time adherence’ retention [21] (Table 1). Similar to the
‘point’ retention definitions, the MOH and WHO reten-
tion definitions assess retention at a single time point.
For women’s attendance at a clinic, we considered differ-
ent types of visits, including medical consultations, phar-
macy drug refills, counseling, or laboratory analysis. This
approach allowed us to consider HIV care as a holistic
strategy, given that HIV care is provided in an increasingly
team-based environment with non-prescribing healthcare
professionals taking on expanded roles in direct patient
care. Table 1 summarizes the definitions of retention ac-
cording to different measures and shows how failure
events were accounted for in statistical analyses.
Statistical analysis
A total of 31,186 HIV-positive women enrolled in the
PMTCT option B+ program in 86 MOH facilities in Nam-
pula and Zambézia Provinces and initiated ART during
the study period. Women’s appointment adherence, as
well as their on-time adherence to scheduled visits, were
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expressed as percentages, median, and interquartile range
[IQR]. Women’s retention status was classified into a bin-
ary outcome (retained vs. not retained in care) using a
75% threshold for clinical attendance. Each woman con-
tributed to the analyses from the date of ART initiation to
the first occurrence of a failure event, as described in
Table 1. To allow sufficient time to analyze clinical attend-
ance within the first year of treatment, we only included
women who initiated ART up until December 31, 2016
and for whom the theoretical follow-up time under ART
was ≥12months.
Kaplan-Meier survival curves were produced to esti-
mate retention in care at 3, 6, 9, and 12months post-
ART initiation using each of the definitions described
above. We assessed variability in the different measures
of retention between respective definitions used. We did
not consider ‘appointment adherence’ retention for the
survival analysis, as this definition does not contemplate
a time event, but rather a total number of visits com-
pleted during the observation period.
We assessed sensitivity, specificity, and the proportion
of misclassified women for each alternative definition of
retention compared to the reference of an ‘ideal case
scenario’ of full ‘on-time adherence’ retention, defined as
a woman alive and in care 12 months post-ART initi-
ation and ≥ 75% of scheduled visits attended on time
(+/− 15 days). Sensitivity and specificity values were cal-
culated with 95% confidence intervals.
Results
Of 31,186 HIV-positive women enrolled in the PMTCT
option B+ program during the study period, 18,739 were
considered as being retained in care at 12months post-
ART initiation according to the ‘point’ retention definition.
Table 1 Retention definitions and methods of calculation. B+ PMTCT program, Mozambique, 2013–2017
Type of retention Definition of a patient ‘alive and retained in care’ at 12 months post-ART
initiation
Failure event
‘Point’ retention Alive and had a visit at the health facility 12 months
post-ART initiation or if was known to have had a visit
at a health facility any time after
Death, LTFU, and transfer-out are counted
if they occurred within the first 12 months
post-ART initiation
WHO Attendance at a health facility at 12 months post-ART
initiationa, or at any time up to 3 months later
Death, LTFU, and transfer-out are counted
if they occurred within the first 15 months
post-ART initiation.
Patients transferred out were right-censored
at the date of transfer-out
MOH Attendance at a health facility at 12 months post-ART
initiationa
Death or LTFU are counted if either occurred
within the first 12 months post-ART initiation
Patients transferred out are excluded from
the analysis
IATT Attendance at a health facility and on treatment at
1, 2, 3, 6, 9, and 12 months post-ART initiation b
Death, LTFU, transfers-out and failure to attend
either the 1-, 2-, 3-, 6-, 9-, or 12-month visit,
whichever comes first




Attendance at a health facility at 12-months post-ART
initiation a and≥ 75% of appointment adherence to
scheduled visits
‘Appointment adherence’ was estimated using the
number of visits attended divided by the number of





Attendance at a health facility at 12 months post-ART
initiation a and≥ 75% of ‘on-time attendance to scheduled
visits
A visit on time is defined as a visit that occurred within
+/− 15 days of the date of the expected scheduled visit
‘On-time adherence’ is estimated using the number of visits
attended on-time divided by the number of total scheduled
visits.
Unscheduled visits occurring before the date of appointment
were not counted as missed visits
Death, LTFU, transfer-out, and failure to attend
a visit on-time, whichever comes first.
Patients were right-censored at the date of the
1st failure event
ART antiretroviral therapy, IATT Inter-Agency Task Team, LTFU lost to follow-up, MOH Ministry of Health, PMTCT for prevention of mother-to-child transmission,
WHO World Health Organization
aFor these definitions, we considered a window period of +/− 15 days around the theoretical date of 12-month post-ART initiation
b We allowed a +/− 15-day window period for each stage of ART follow-up. Note: We did not consider ‘appointment adherence’ retention for the survival analysis,
as this definition does not contemplate a time event but rather the total number of visits completed during the observation period
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We excluded 1899 women with a follow-up ART time of
< 12months. Finally, 16,840 women were included in this
study.
Of 16,840 women included, only 2764 (16%) and 407
(2%) were considered retained at 12 months post-ART
initiation when considering regularity and timeliness of
appointment attendance, respectively (Fig. 1). The oc-
currence of irregular (IATT definition) and delayed (‘on-
time’ definition) clinical attendance was documented as
early as 2–3 months post-ART initiation. For all women
included, the median appointment adherence was 66.7%
(IQR 57.1–80.0%) and the median on-time adherence
was 40.0% (IQR 22.2–52.9%) during the 12-month ob-
servation period.
Figure 2 shows Kaplan-Meier survival curves for reten-
tion over time up to 12-month post-ART initiation using
the different definitions. Among the 16,840 B+ pregnant
women considered retained in care according to the
‘point’ retention definition, 84.8% (95% CI 84.2–85.3)
were actually defined as retained in care when estimated
using the WHO definition (i.e. attendance at a health fa-
cility up to 15 months post-ART initiation), 60.3% (95%
CI 59.6–61.1) with the MOH definition (i.e. alive and in
care at 12 months post-ART initiation), and 16.4% (95%
CI 15.8–17.0) with the IATT definition (i.e. alive and on
treatment at 1, 2, 3, 6, 9, and 12months post-ART initi-
ation), respectively. When using the ‘on-time adherence’
retention definition (i.e. alive and in care at 12 months
post-ART initiation with at least 75% of on-time adher-
ence during follow-up), only 1.2% (95% CI 1.0–1.4) were
defined as retained in care.
We considered the reference category to be the 407
women alive and in care 12-months post-ART initiation
with at least 75% on-time adherence. We calculated the
sensitivity and specificity of other definitions to more ac-
curately classify the women into a more suitable cat-
egory of retention and determine the proportion of
misclassified patients. While all definitions provided spe-
cificity rates of ≥98%, the sensitivity to detect a patient
actually retained in care with ≥75% of on-time adher-
ence was < 12% (Table 2). The WHO and MOH reten-
tion definitions provided the lowest sensitivity figures
and the highest proportion of women misclassified as
retained in care, as follows: 3.0% sensitivity (95% CI 2.7–
3.3%) with 78% of patients misclassified according to the
WHO definition and 4.3% sensitivity (95% CI 3.9–4.7%)
with 54% of patients misclassified according to the
MOH definition. In addition, the ‘point’ retention defin-
ition misclassified 97.6% of patients. Although sensitivity
rates were also low when using the IATT and ‘appoint-
ment adherence’ retention definitions, the proportion of
misclassified patients was relatively smaller (15.9 and
18.3%, respectively).
Discussion
We analyzed six different definitions of ‘retention in
care’ for HIV-positive pregnant women enrolled in
PMTCT option B+ programs, ranging from the most le-
nient definition using a ‘point’ retention approach to the
most stringent definition using an ‘on-time adherence’
retention approach. Of the six definitions, three assess
retention at a single time point (‘point’ retention, WHO,
and MOH). The IATT, ‘appointment’, and ‘on-time ad-
herence’ retention definitions reflect a more continuous
engagement in care, in which follow-up visits between
initiation of ART and the endpoint date are considered.
Fig. 1 B+ pregnant women retained in care 12 months post-ART initiation: time to first failure event
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Fig. 2 Estimated Kaplan-Meier survival curves for retention over time, by retention definition
Table 2 Sensitivity and specificity of various definitions of retention in care among B+ HIV+ pregnant women defined as alive and
retained in care according to the ‘point’ retention definition (n = 16,840)
Retained in care according to
type of definition (n = 16,840)
Alive and retained in care with ≥75% of
visits in time (Reference)
Sensitivity 95% CI Specificity 95% CI % of
misclassification
Yes No
‘Point’ retention 407 16,433 – – 97.6%
WHO 405 13,154 3.0% [2.7–3.3%] 99.9% [99.8–100%] 78.1%
MOH 407 9093 4.3% [3.9–4.7%] 100% [99.9–100%] 54.0%
IATT 249 2515 9.0% [8.0–10.1%] 98.9% [98.7–99.0%] 15.9%
‘Appointment adherence’ retention 407 3076 11.7% [10.6–12.8%] 100% [100–100%] 18.3%
The ‘on-time adherence’ definition of retention is considered as the reference (n = 407 women retained in care at 12-months post-ART initiation and with ≥75%
on-time adherence to scheduled visits). The percentage of misclassified patients is calculated using the sum of patients incorrectly classified according to each
definition divided by the total number of patients included in the analysis
CI confidence interval, IATT Inter-Agency Task Team, MOH Ministry of Health, WHO World Health Organization
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As expected, we found that the more stringent the def-
inition, the lower the probability for women to be de-
fined as retained in care; when levels of attendance at
visits during follow-up were considered, estimates were
even lower (85 and 60% when using the WHO and
MOH definitions compared to 16 and 1% when using
the IATT and ‘on-time adherence’ retention definitions).
At the end of the first year, most women starting ART
had not adhered to their scheduled visits, with median
appointment adherence at 66% and median on-time ad-
herence at 40% among the 16,840 women considered as
retained in care using the ‘point’ retention definition. Of
these, only 16 and 2% were actually defined as retained
in care 12 months post-ART initiation if a threshold of
≥75% for appointment and on-time attendance were
considered, respectively.
Initial visits in the first year of ART initiation are crit-
ical to ensure successful engagement in care, as they
convey important preventive healthcare and risk reduc-
tion messages, involve intensive counseling, peer sup-
port, and monitor patterns of healthier behavior for the
women and their exposed children. This interaction be-
tween the health system and the HIV-infected woman
determines the survival likelihood of the pair and the
mother-to-child transmission of HIV. Adding the fre-
quency and regularity of visits into the concept of re-
tention increases the quality of the PMTCT program
evaluations, enabling a distinction to be made be-
tween women who attend for all, or some care and
treatment, and those who completely fail to attend
scheduled visits and are therefore considered not to
be engaged in care.
Table 3 provides a summary of the advantages, limita-
tions, and programmatic implications of the six measures
of retention for PMTCT option B+ programs. Based on
our results, the three-single time point measures, namely,
the ‘point’, WHO, and MOH definitions, were classic pro-
grammatic approaches for measuring retention in care
under ART. While relatively easy to use, they do not cap-
ture important milestones in the PMTCT context; for ex-
ample, at delivery, at 2-month post-partum for early infant
diagnosis, or at the end of breastfeeding for the final HIV
determination of the HEI. In addition, they do not con-
sider visit consistency, which has been demonstrated to be
significantly associated with ART adherence and viral sup-
pression among HIV-positive adults [22, 23]. However, the
three definitions that capture visit consistency along the
continuum of care, namely, the IATT, ‘appointment’, and
‘on-time adherence’ definitions, were more complex to use
as they included multiple clinic visits (repeated measures)
occurring longitudinally over time. This could become ex-
tremely challenging in limited-resource settings where lim-
ited qualified human resources are available to document
such information, data collection tools are not adapted to
capture longitudinal follow-up, and there are numerous
entry points where women are followed-up within the
same health facility or between sites [14, 24]. To correctly
capture patients’ follow-up, different data sources need to
be combined or triangulated, for example, with counseling
registers and laboratory or pharmacy records. Electronic
databases may help in this process, but these are generally
implemented in high volume, accessible sites and may not
necessarily be representative of the entire country for na-
tional programs. However, all three definitions enabled
adding the concept of a continuum of care to point reten-
tion estimates.
When considering ‘on-time adherence’ retention as
the reference, all other definitions provided very low
sensitivity rates to accurately detect patients retained in
care, with high rates of misclassified patients. The WHO
and MOH retention definitions provided the lowest sen-
sitivity rates, of 3 and 4%, respectively. For the ‘point’ re-
tention, WHO, and MOH definitions, which do not
consider continuous follow-up in their calculations, the
proportion of misclassified patients ranged from 54 to
97%. The ‘appointment adherence’ definition provided
the highest sensitivity rate (11.7%), with a fairly low pro-
portion of misclassified patients (18.3%) compared to all
other definitions analyzed. We found that the median
time to first failure of correct follow-up was short (≤3
months), if visit attendance during follow-up was consid-
ered, which demonstrates the need to implement early
measures to prevent patients in the PMTCT program
from disengaging from care. Such strategies should focus
on already well-known barriers to regular attendance,
such as a lack of disclosure, poor staff attitudes, compet-
ing personal priorities, medication side-effects, or trans-
portation difficulties [21].
While our definition of ‘on-time adherence’ retention
represents the ideal situation, in which an HIV-positive
pregnant woman who enrolls in a PMTCT program and
starts ART under option B+ should be considered as
fully engaged in care to ensure an optimal viral response,
it is perhaps too stringent for PMTCT program evalua-
tions. This definition is also time consuming to use on a
routine basis and may not be compatible with current
PMTCT service settings. Therefore, we recommend
using either the IATT or the ‘appointment adherence’
retention definitions to better measure levels of engage-
ment in care for mother-infant pairs.
Our analysis had several limitations. To accurately
evaluate attendance at scheduled visits, it is desirable to
distinguish visits canceled in advance (either by the pa-
tient or the care provider) from ‘no show’ visits that are
missed by the patient [13]. Our data did not allow for
this distinction to be made, as this information was not
captured in the database. Therefore, our results may
have underestimated the real values of women’s
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engagement in care when analyzing ‘appointment’ and
‘on-time’ adherence retentions.
Some women, although categorized as having full attend-
ance at scheduled visits, did not follow per se the recom-
mended schedule of visits according to national guidelines.
More frequent visits may indicate a more advanced HIV
disease, problems in counseling that need to be addressed,
or drug or laboratory reagent stock-outs [24]. Less frequent
clinical visits may reflect a stabilized disease stage or tem-
porary silent transfers (i.e. women receiving ART services
elsewhere for a short period of time). For this reason, we
chose to use all scheduled visits, regardless of whether the
visits fell into expected time intervals. For similar reasons,
we did not analyze treatment interruptions and gaps in
care. Further research is warranted to investigate the effect
of a lack of observation of the recommended schedule of
visits as per national guidelines on PMTCT program
outcomes.
Finally, we analyzed data from health facilities with
ePLD in two provinces in Mozambique. Although these
two provinces are among the most populated in the coun-
try, with large volumes of patients seen at health facilities,
Table 3 Advantages, limitations, and programmatic practicality of six measures of retention in care for PMTCT option B+ programs
Retention definition Advantages Limitations Programmatic practicality
‘Point’ retention Easy to measure
Assessed at a single time point
Provide a transversal picture of retention
Does not consider visit consistency
of the MIP
Does not consider whether the
women fully adhered to the
12-month visit schedule
Not aligned with important
PMTCT milestones (i.e. delivery,
EID, or final HIV testing)
Programmatic definition of retention
Achievable with simple health
information systems (e.g. paper-
based registers)
WHO Easy to measure
Assessed at a single time point
Provide a transversal picture of retention
More specific in detecting patients adhering
to the 12-month visit (up to 15-months only)
Does not consider visit consistency
of the MIP
Not aligned with important PMTCT
milestones (i.e. delivery, EID, or the
end of breastfeeding)
As above
MOH Easy to measure
Assessed at a single time point
Provides a transversal picture of retention
Considers whether the women fully adhered
to the 12-month visit schedule
As above Programmatic definition of retention
Achievable with simple health
information systems (e.g. paper-
based registers)
Cohort based approach for
calculation
IATT Considers whether the women fully adhered
to the 12-month visit schedule
Captures visit consistency
Can be adapted to align with the follow-up
of the MIP
More complex to measure
(ideally requires an ePLD or
POC EMR)
Not systematically aligned with
national PMTCT follow-up guidelines
but can be modified accordingly
Probable need of data triangulation
with other data sources (e.g.
pharmacy, laboratory) and linkage
with unique IDN
Relevant in capturing visit
consistency of the MIP, can be
aligned with important PMTCT
milestones
Ideal if integrated POC testing
services for the MIP are available




Considers whether the women truly
adhered to the 12-month visit schedule
Capture visit consistency
Measurable with paper-based longitudinal
cohort based registers (total # of completed
visits done/total scheduled visits)
Does not capture the regularity or
timeliness of completed visits
Not aligned with important PMTCT
milestones for the MIP
Highly dependent on data completeness
of denominator (# of scheduled visits)
Need of data triangulation with other
data sources (e.g. pharmacy, laboratory)
and linkage with unique IDN
Achievable with simple health
information systems




Considers whether the women fully
adhered to the 12-month visit schedule
Ideal to capture correct levels of
engagement in care for PMTCT
(regularity and timeliness)
Aligned with important milestones of
PMTCT follow-up for the MIP
More complex to measure (requires an
ePLD or POC EMR)
Highly dependent on data completeness
of denominator (# of scheduled visits)
Need of data triangulation with other
data sources (e.g. pharmacy, laboratory)
and linkage with unique IDN
Time consuming activity not compatible
with one-stop model PMTCT services in
the absence of electronic databases
Adapted for research purposes
Not compatible with routine
monitoring of retention in care
of MIPs
EID early infant diagnosis, EMR electronic medical record, ePLD electronic patient-level database, IATT Inter-Agency Task Team, IDN identification number, MIP
mother-infant pair, MOH Ministry of Health, POC point-of-care, PMTCT for prevention of mother-to-child transmission, WHO World Health Organization
Ahoua et al. BMC Public Health          (2020) 20:322 Page 8 of 10
our results may not be generalizable to other regions in
Mozambique or to other resource-limited settings.
Conclusion
Our findings suggest that women’s engagement to care
cannot be precisely assessed without taking into account
their presence at key time-points along the continuum
of care. Lack of agreed definition hinders comparison of
findings from different programs. We recognize that cap-
turing timeliness and regularity of women’s clinical at-
tendance with routine data can be a complex task and
that applying more stringent definitions is likely to result
in lower rates of retention in care in PMTCT programs.
Nonetheless, HIV services should improve its monitoring
systems to ensure that clinical decision be made based on
sound and timely assessment of women’s retention and
key indicators related to maternal viral load, infant
prophylaxis or infant HIV serostatus determination. A
consensus on universal definition is urgently needed; how-
ever, data availability, diverse clinical practices in different
settings, and local analytical capacities should be taken
into account to ensure practicability of the definition.
Since retention estimates are used for the modeling of ver-
tical transmission rates of HIV, lack of precision could
lead to false interpretation of program achievements in re-
lation to elimination of mother-to-child transmission of
HIV. This consideration may become particularly import-
ant as recent data seems to indicate a stagnation in the
achievements of PMTCT programs worldwide, which sug-
gests the need for revised global, national, and local strat-
egies to end the HIV epidemic by 2030.
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